Achaogen Lands $60 Million Biomedical Advanced Research and Development Authority (BARDA) Contract
4/24/2013 11:28:16 AM
More...
|
Achaogen Announces All Objectives Met in Phase 2 Plazomicin Complicated Urinary Tract Infections Study and Start of First-in-Human Study with ACHN-975
5/15/2012 10:33:55 AM
More...
|
Achaogen Appoints Chief Medical Officer Kenneth Hillan to Chief Executive Officer
9/28/2011 9:51:18 AM
More...
|
Achaogen Appoints Kenneth J. Hillan, M.B. Ch.B., to Chief Medical Officer
3/23/2011 11:07:51 AM
More...
|
Achaogen to Present New Data on ACHN-490 at the 50th Annual ICAAC Meeting
9/10/2010 8:47:44 AM
More...
|
Achaogen Awarded Contract Worth up to $64 Million by Biomedical Advanced Research and Development Authority (BARDA) for the Development of ACHN-490
8/31/2010 6:33:14 AM
More...
|
Achaogen Completes $56 Million Series C Financing
4/7/2010 6:53:46 AM
More...
|
Achaogen Announces ACHN-490 Clinical Data at the 49th Annual ICAAC Meeting
9/14/2009 11:24:41 AM
More...
|
Achaogen Appoints John C. Doyle to the Newly Created Position of Chief Operating Officer
8/25/2009 9:32:40 AM
More...
|
FierceBiotech Names Achaogen as One of the "Fierce 15" Biotech Companies of 2009
6/30/2009 9:02:30 AM
More...
|
|